Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI® (larotrectinib) capsules, for oral use VITRAKVI® (larotrectinib) oral solution Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-prescription
VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test [see Dosage and Administration (2.1)].
- generic_name
- larotrectinib
- product_names
- LAROTRECTINIB
- ndc
- 50419-390, 50419-390-01, 50419-391, 50419-391-01, 50419-392, 50419-392-01, 50419-393, 50419-393-02, 50419-393-03
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en